Shenzhen Hanyu Pharmaceutical Co., Ltd. (abbreviation: John-medicine, stock code: 300 199) is specialized in peptide drug development, production and sales of state-level high-tech enterprises, is located in Shenzhen High-tech Zone in the Central Technology Road 37. Build a national high-tech industrialization demonstration projects peptide drug production base, the state public test center polypeptide of innovative drugs, peptide drug preparation of national technology platform in the test, Guangdong Province, engineering peptide drug research and development center.

John-Pharmaceutical adhering to "the world's Road, benevolence for the drug," the core values, firmly establish the "primary responsibility for the quality of medicines" and consciousness, to comply with "drug Management Act "and other national laws, regulations and policies, in strict accordance with the GMP production management and quality control, based on the digestion by the introduction of independent innovation model, breaking the peptide drug bottlenecks in large-scale production technology. Has applied for 38 patents and has patents 5, the National Certificate of seven new drugs, new drug approval documents five clinical trials, drug registration approval document 45. The main medicines used in gastrointestinal, cardiovascular, diabetes, infectious diseases, cancer and age-related diseases such treatment. The company has undertaken a national "863 Program", the state "15", "Eleventh Five-Year" major science and technology, state-level Torch Program, the state "significant Drug Discovery", and Guangdong Province, a major science and technology, research, major breakthroughs in key areas 20 number of major scientific and technological projects. 4 consecutive years, "the Shenzhen Municipal Science and Technology Innovation Award" and won the "Shenzhen key product innovation", "Guangdong Science Technology Award" each one. 2008 by the Shenzhen Municipal People's Government awarded "Shenzhen innovation industry leaders," the title; was identified in 2009 as "National High-tech Enterprise"; 2010 by the National Development and Reform Commission awarded the "National High-tech industrialization demonstration of new peptide drugs Project "title; 2011 by the China Securities Regulatory Commission for approval, John-Pharmaceutical IPO and listing on the GEM, and has become the first shares of synthetic peptides.

recent years, the company's sales, profits and other operating metrics rapid growth. In 2007 the company was named "China's most-growth technology enterprises 100." 2008 was named "Deloitte China high-tech, high-growth 50" company. 2009 was selected as the "Qing dynasties - Most Investment Value 50", "Entrepreneur 100." 2010 by "Forbes" magazine as "2010 China Top 200 Enterprises potential" and ranked 59th.

John-medicine with a group from the United States, Canada, Britain and other countries of returned overseas students and technical personnel engaged in peptide drug R & D personnel total number of employees accounted for nearly 30%. Approved by the Guangdong Provincial Science and Technology Department, there are two resident companies engaged in science and technology correspondent school-enterprise cooperation and research projects. In addition, with many research institutes to establish a close working relationship, hired a number of well-known experts as technical advisers.

John-medicine is currently the synthetic peptide has one of the largest varieties of drugs, the main product Desmopressin acetate injection, injection thymopentin peptide, somatostatin injection, injection of terlipressin are among the best in the domestic market share, which was also selected as terlipressin Reed Sinopharm National Drug Fair "2009 China top ten blockbuster new prescription drugs."

construction of national high-tech industry peptide drug production base in Shenzhen Greeting national biological medicine base, built strictly in accordance with cGMP standards in Europe and America, by the Shenzhen Municipal Committee, government as the "five-second" period reflect the new path for future urban development in Shenzhen and the new direction of industrial transformation and upgrading 60 major landmark building projects.